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Clindamycin is increasingly used to treat canine pyoderma. Eight of 608 Staphylococcus pseudintermedius isolates were positive
for inducible clindamycin resistance by double-disk diffusion testing and PCR detection of ermB. Staphylococcus pseudinterme-
dius isolates that are erythromycin resistant but clindamycin susceptible by in vitro antimicrobial susceptibility testing should
be tested for inducible clindamycin resistance.
Increased prevalence of methicillin resistance and multidrug re-sistance in Staphylococcus pseudintermedius has resulted in
greater use of clindamycin to treat canine pyoderma because of its
perceived clinical efficacy and good distribution into the skin (1,
2). Clindamycin is a lincosamide that reversibly binds to the bac-
terial 50S ribosomal subunit, thereby inhibiting protein synthesis
(3). In some cases, staphylococci may appear to be susceptible to
clindamycin when tested in vitro, but the infected patient may fail
to respond to therapy despite being treated with what seems to be
an appropriate drug concentration for an appropriate duration.
Lincosamides bind to the same or closely related binding sites in
the bacterial ribosome as macrolides such as erythromycin. Resis-
tance to macrolide, lincosamide, and streptogramin B antibiotics
(MLS phenotype) can occur through acquisition of a methylase
enzyme that removes a methyl group from an adenine residue in
the 23S rRNA component of the 50S subunit of the ribosome
(4–6). Removal of this methyl group alters the site to which the
antimicrobial drug binds, altering its efficacy. An active efflux
pump encoded by the msrA gene also confers resistance to mac-
rolides and streptogramin antibiotics but not lincosamides such as
clindamycin (MS phenotype) (6).
Approximately 40 erm genes that encodemethylases have been
reported in different bacterial genera, with ermA, ermB, and ermC
the genes most commonly found among staphylococci (7). In
Staphylococcus aureus, ermA and ermC confer erythromycin resis-
tance in 94 to 98% of isolates (8). In S. pseudintermedius, ermB is
responsible primarily forMLS resistance, but its expression can be
constitutive or inducible (9). Detailed descriptions of the mecha-
nisms of erm gene expression and mutations leading to constitu-
tive MLS resistance have been previously published (10, 11). Mu-
tation in the macrolide-inducible DNA sequence preceding ermB
genes can alter resistance from inducible to constitutive (10).
These mutations occur at a rate of about one in every 2  106
replications (11, 12). Infections in which bacteria are present and
dividing in purulent material in numbers greater than this are
common, whichmeans that thesemutations readily occur, result-
ing in constitutive MLS resistance, and strains carrying the muta-
tion will dominate within the bacterial population at the site of
infection, particularly in the presence of antimicrobial selection
pressure (10). Therefore, if bacteria carrying inducible MLS resis-
tance are present in an infection, mutations may result in consti-
tutive MLS resistance leading to treatment failure. Routine anti-
microbial susceptibility testing can detect constitutive MLS
resistance but fails to detect inducible resistance (13). Inducible
clindamycin resistance should be suspected in isolates that are
erythromycin resistant but clindamycin susceptible upon in
vitro antimicrobial susceptibility testing. In this study, we eval-
uated the frequency of inducible clindamycin resistance in S.
pseudintermedius from patients presented to the Texas A&M
Veterinary Medical Teaching Hospital (VMTH) by using dou-
ble-disk diffusion testing (D-test) for inducible clindamycin
resistance and the presence of ermB by PCR.
A total of 608 canine Staphylococcus pseudintermedius isolates
collected from the VMTH between 2007 and 2012 were screened
for inducible clindamycin resistance. At the time of initial collec-
tion, all isolates were presumptively identified as S. pseudinterme-
dius based on Gram stain, colony color, polymyxin B susceptibil-
ity, production of coagulase and catalase, and ability to grow on
salt-mannitol agar. All isolates were tested for antimicrobial suscep-
tibility using commercially available systems (Vitek [bioMérieux,
Durham, NC] or TREK Sensititre [TREK Diagnostics, Cleveland,
OH]) according to the Clinical and Laboratory Standards Insti-
tute (CLSI) guidelines forMIC testing (14). Isolates were screened
to identify those that were intermediate or resistant to erythromy-
cin and susceptible or intermediate to clindamycin. Those meet-
ing the criteria were further tested for the presence of a positive
D-test according to the CLSI guidelines (15). Quality control
strains for antimicrobial susceptibility testing included S. aureus
ATCC 43300, ATCC 25923, and ATCC 29213. Quality control
strains for the D-test included S. aureus BAA-977 and BAA-976.
All quality control strains were obtained from the American Type
Culture Collection (Manassas, VA). Eight isolates met the screen-
ing criteria and underwent further testing. All eight were suscep-
tible for clindamycin on the MIC panel; seven were erythromycin
resistant and one was intermediate to erythromycin. One isolate
exhibited intermediate resistance to clindamycin; however, it was
susceptible to erythromycin and was not tested further. Species
identification of the eight isolates was confirmed by PCR using
primers and methods previously described (16). Bacterial DNA
was purified for the ermBPCRusing aDNeasy blood and tissue kit
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(Qiagen, Germantown, MD) according to the manufacturer’s in-
structions for Gram-positive bacteria. PCR amplification of a
639-bpproduct specific for ermBwas performedusing primers (5)
and methods (17) previously described, with an alteration in
the annealing temperature to 46°C followed by 1%gel electropho-
resis. All primers and PCR reagents were purchased from
Sigma-Genosys, Houston, TX, and TaKaRa Bio Company, Otsu,
Shiga, Japan, respectively. The resultant PCR product was con-
firmed as ermB by sequencing at the DNA Core Laboratory at the
Texas A&M University College of Veterinary Medicine.
The isolates in this study came from eight dogs that presented
to theVMTHbetween February 2008 andApril 2010. Two isolates
were collected from each of the following sites: infected tibial pla-
teau leveling osteotomy (TPLO) implants, skin lesions, and the
urinary tract (one from an infection and one from a bladder
stone). One of the skin lesion isolates came from a dog with gen-
eralized demodicosis and deep pyoderma, and the second was
collected from the prescrubbed surgical site for a torn cranial
cruciate ligament repair. The remaining two isolates came from a
blood culture and postsurgical lavage of the peritoneum following
exploratory abdominal surgery.
Upon presentation to the VMTH, six of the eight dogs had
received prior antibiotic therapy with one or more antimicrobial
drugs within 6 weeks of entering the hospital. Five of these dogs
were receiving antimicrobial therapy at the time of culture. One
dog received erythromycin, and another received clindamycin. In
this study, all isolates considered resistant or intermediate to
erythromycin but susceptible to clindamycin in vitro tested posi-
tive for inducible clindamycin resistance by D-test and the pres-
ence of ermB associated with MLS resistance (Table 1 and Fig. 1).
Two of the isolates were methicillin susceptible (25%), while the
remaining six were methicillin resistant (75%).
S. pseudintermedius is the most common bacterial agent iso-
lated from canine pyoderma and surgical and nonsurgical
wound infections (18, 19). Of the eight dogs that provided
isolates evaluated in this study, four had skin lesions or TPLO
implant-related surgical infections. Treatment of staphylococ-
cal infection at these sites in dogs typically involves therapy
with -lactam antibiotics, such as penicillins and cephalospo-
rins. With increased prevalence of methicillin resistance, alter-
natives to -lactam antibiotics have been sought (1, 20). In
addition to being resistant to -lactam antibiotics, methicillin-
resistant S. pseudintermedius (MRSP) strains are increasingly
resistant to other antibiotics. A recent multicenter study in
Europe and North America showed that MRSP isolates are
commonly resistant to virtually all classes of antibiotics ap-
proved for use in dogs (19, 21). Six of the isolates in this study
were MRSP strains, while two were methicillin susceptible. In
methicillin-resistant Staphylococcus isolates from North Amer-
ica collected from 2006 to 2008, 17.7% (11/62) of S. aureus
isolates carried inducible clindamycin resistance compared to
0% (0/46) of S. pseudintermedius isolates (22). In MRSP iso-
lates from Europe and North America collected from 2004 to
2009, 1.9% (2/103) of isolates were positive for ermB and dis-
played inducible resistance to clindamycin (9). In the study
described here, the differences in inducible clindamycin resis-
tance could be attributed to either rapid changes in antimicro-
bial resistance patterns or geographic differences in the occur-
rence of inducible resistance.
Increased methicillin resistance and inducible clindamycin re-
sistance in S. pseudintermedius has significant implications for ca-






11-001 0.5 (S) 8 (R) 8 (R) Positive Positive
11-025 0.5 (S) 8 (R) 8 (R) Positive Positive
11-033 0.5 (S) 1 (I) 8 (R) Positive Positive
11-064 0.5 (S) 8 (R) 8 (R) Positive Positive
12-012 0.5 (S) 8 (R) 0.25 (S) Positive Positive
17-016 0.5 (S) 8 (R) 2 (R) Positive Positive
18-007 0.5 (S) 8 (R) 8 (R) Positive Positive
24-014 0.5 (S) 8 (R) 0.25 (S) Positive Positive
a MIC for clindamycin, erythromycin, and oxacillin. Breakpoints for antimicrobials were from CLSI VET01-A4 (15). Abbreviations for interpretations are as follows: R, resistant to
antimicrobial; S, susceptible to antimicrobial; I, intermediate susceptibility to antimicrobial. Guidelines for D-test performance and interpretation were from CLSI M02-A11 (15).
FIG 1 Disk diffusion testing for inducible clindamycin resistance of Staphy-
lococcus pseudintermedius isolates. The disk labeled E15 contained 15 g of
erythromycin, and the disk labeled CC2 contained 2 g of clindamycin. The
disks are spaced 15 mm apart. (A) Staphylococcus aureus ATCC 25923, eryth-
romycin and clindamycin susceptible, negative D-test; (B) S. pseudintermedius
clinical isolate 11-012, erythromycin and clindamycin resistant, negative D-
test; (C) S. aureus BAA-976, erythromycin resistant, clindamycin susceptible,
negativeD-test; (D) S. aureusBAA-977, erythromycin resistant, inducible clin-
damycin resistant, positive D-test.
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nine and human health. While S. pseudintermedius infection in
humans is relatively uncommon, zoonotic transmission of S.
pseudintermedius to the owner of an infected pet or veterinary staff
is a potential threat (18, 23). Recent studies have demonstrated
that 5.3% of veterinary dermatologists and their technical staff
carry MRSP and that owners of dogs with deep pyoderma can
carry S. pseudintermedius strains identical to those carried by their
infected pets (18, 24). Additionally, there is the potential for trans-
mission of antimicrobial resistance genes fromcanine isolates of S.
pseudintermedius to human isolates of S. aureus (25, 26).
For empirical, systemic treatment of canine pyoderma,
amoxicillin-clavulanate and first-generation cephalosporins
are the most common first-line drugs selected (2). With in-
creased occurrence of antimicrobial resistance, clindamycin is
recommended as an appropriate, alternative choice due to its
favorable safety profile, clinical efficacy, and distribution into
the skin (1, 2). Infections refractory to empirical therapy
should be cultured and isolated bacteria tested for antimicro-
bial susceptibility. S. pseudintermedius isolates that are resis-
tant tomacrolides such as erythromycin but susceptible to clin-
damycin should be tested for the presence of inducible
clindamycin resistance either by D-test or genetic testing.
While the occurrence of such isolates is relatively low (1.32%
[8/608] in our study), failure to detect these isolates can result
in treatment failures in infected patients and associated in-
creased patient morbidity and expense for clients. In two of the
cases presented here, clindamycin was used for antibiotic ther-
apy, resulting in treatment failure. Clinicians must recognize
the potential for inducible clindamycin resistance and be able
to recognize the potentially predictive pattern on antimicrobial
susceptibility results. Performing the D-test is not a standard
practice in all microbiology laboratories. The laboratory
should be asked to perform this test whenever an S. pseudinter-
medius isolate is reported as susceptible (or intermediate) to
clindamycin while resistant (or intermediate) to erythromycin
with in vitro antimicrobial susceptibility tests (27).
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